GeneNews announces management changes to support commercialization of Colon...(ransition from development to commercial...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
GeneNews announces management changes to support commercialization of ColonSentry(TM)
Date:6/2/2008
ransition from development to commercialization," said Dr. Dreismann. "GeneNews has developed important technology that is expected to positively impact the molecular diagnostic field."
About GeneNews
--------------
GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on GeneNews, visit http://www.genenews.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.
'/>"/>
| SOURCE GeneNews Limited Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
4. GeneNews receives ISO 13485 accreditation
5. GeneNews selected to present late-breaking abstract at AACR Annual Meeting
6. GeneNews announces 2007 year end results
7. GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR
8. GeneNews Announces First Quarter Results
9. Genenews adds two members to its Board of Directors
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
Breaking Biology Technology:Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Vivakor Confirms Record Date of Stock Dividend 2Vivakor Confirms Record Date of Stock Dividend 3
[0] Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. [0] WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening[0] RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE)[0] Vivakor Confirms Record Date of Stock Dividend
Other Biology Technology:Probiotic good bugs may control gut infections 2Two nanostructures are better than one 2Two nanostructures are better than one 3Two nanostructures are better than one 4NASA technology forms the basis for a new nanotechnology company 2
Breaking Biology News(10 mins):Genome BC collaborates with Chile and Norway to sequence salmon genome 2White, but not pure 2White, but not pure 3Munich lab demonstrates diesel truck engine with barely measurable emissions 2Munich lab demonstrates diesel truck engine with barely measurable emissions 3Natural Soy Component May Help Treat Colon Cancer 62125 1Natural Soy Component May Help Treat Colon Cancer 62125 2Holiday Eating Without the Guilt or the Pounds 62122 1Holiday Eating Without the Guilt or the Pounds 62122 2Holiday Eating Without the Guilt or the Pounds 62122 3Providence Service Corporations LogistiCare Subsidiary Announces Non Emergency Medical Transportation Contracts Worth Over 2411 Million Annually in F 62119 1Providence Service Corporations LogistiCare Subsidiary Announces Non Emergency Medical Transportation Contracts Worth Over 2411 Million Annually in F 62119 2Providence Service Corporations LogistiCare Subsidiary Announces Non Emergency Medical Transportation Contracts Worth Over 2411 Million Annually in F 62119 3
Other Biology News:New study predicts where corals can thrive 2Fishing throws targeted species off balance, Scripps study shows 2Fishing throws targeted species off balance, Scripps study shows 3Are humans hardwired for fairness? 2
Biology Products:
Human Protein Phosphatase 2A alpha (PP2Aa) from UpstateLabel IT siRNA Tracker TM Rhodamine Kit with TransIT-siQUEST Reagent from Mirus Bio CorporationLabel IT siRNA Tracker CX Rhodamine Kit with TransIT-siQUEST Reagent from Mirus Bio CorporationCorning Cryo Box For Internal Thread Vials Only,100 Position,1-2 ml,Non-Sterile from Sigma-Aldrich
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |